Abstract: Novel cyclohexyl-1,4-diamine compounds corresponding to formula I, processes for the production thereof, pharmaceutical compositions containing these compounds, methods of producing pharmaceutical compositions including these compounds and related methods of treating or inhibiting certain diseases or conditions.
Abstract: A process for making a compound of formula 1 or a salt thereof, wherein: R1 and R2 are each independently H, halogen, or C1-4-alkyl, or R1 and R2 together are C1-6-alkylene; and R3 is H, halogen, OH, C1-4-alkyl, or O—C1-4-alkyl, the process comprising: (a) reacting a compound of formula 6 wherein R4 is benzyl, diphenylmethyl, or trityl, each optionally substituted at, if available, an aryl group or an aliphatic carbon atom, with a compound of formula 7 or a salt thereof, to obtain a compound of formula 5, or a salt thereof (b) reducing the nitro group of the compound of formula 5 to an amine group and mesylating this amine group and cleaving the protecting group during the reduction step or after the mesylation step to obtain the compound of formula 1.
Type:
Grant
Filed:
October 25, 2006
Date of Patent:
September 9, 2008
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Marco Santagostino, Werner Rall, Rainer Soyka
Abstract: Ionic compounds which are liquids at room temperature are formed by the method of mixing a neutral organic liqand with the salt of a metal cation and its conjugate anion. The liquids are hydrophobic, conductive and stable and have uses as solvents and in electrochemical devices.
Abstract: The present invention provides a new process for the preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamide hydrochloride, wherein this compound is prepared directly from the chloromethylalcohol. Importantly, the process of the present invention results in higher yields of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamide hydrochloride without sacrificing its purity. The processes of the present invention can be used to prepare not only the 2S,3S-derivative, but also the 2R,3S-, 2S,2R- and the 2R,3R-derivatives.
Type:
Grant
Filed:
February 7, 2005
Date of Patent:
August 19, 2008
Assignee:
Aerojet Fine Chemicals LLC
Inventors:
Aslam A. Malik, Hasan Palandoken, Joy A. Stringer, Roland P. Carlson, John Leach, Thomas G. Archibald, Robert G. Miotke
Abstract: The invention generally relates to methods of forming vinyl(thio)carbamates and more particularly to a vinylchloroformate-free method of synthesizing (N-vinyloxycarbonyl)-3-aminopropyltris(trimethylsiloxysilane).
Type:
Grant
Filed:
January 27, 2005
Date of Patent:
July 22, 2008
Assignee:
Bausch & Lomb Incorporated
Inventors:
David E. Seelye, Jay F. Kunzler, Joseph C. Salamone
Abstract: A high purity aqueous solution of hydroxylamine product is prepared by treating an aqueous solution of hydroxylammonium salt with a base like ammonia at low temperatures. A novel process can be carried out by separating the ammonium salt side product from hydroxylamine with a low temperature filtration and a resin-exchange process. The concentration of the hydroxylamine product is further improved by a safe distillation process that produces a high purity and high concentration hydroxylamine product with reduced risks of explosion.
Type:
Grant
Filed:
January 26, 2004
Date of Patent:
July 8, 2008
Assignee:
San Fu Chemical Company, Ltd.
Inventors:
Kaung-Far Lin, Jin-Fu Chen, Wei Te Lin, Ruey-Shing Chen, Kung-Chin Kuo
Abstract: A process for preparing a 3-aminophenylacetylene compound of formula (5), including: a) reacting a 3-haloaniline compound of formula (1) with an acetylene compound of formula (2) in the presence of a palladium compound, a copper compound, and an amine compound of formula (3) to form an aniline compound of formula (4); b) precipitating the aniline compound of formula (4) in the form of a crystal, and isolating it by solid/liquid separation; and c) reacting the aniline compound of formula (4) with a base to obtain 3-aminophenylacetylene.
Abstract: The present invention relates to lamotrigine, a useful agent for anti-epilepsia. New crystal forms of lamotrigine containing molecules of the solvent in stoichiometric ratios are disclosed. The present invention also provides processes for preparing the new crystal forms of lamotrigine.
Type:
Grant
Filed:
January 31, 2005
Date of Patent:
June 24, 2008
Assignee:
Teva Pharmaceutical Industries Ltd.
Inventors:
Nissim Garti, Yana Berkovich, Ben-Zion Dolitzky, Judith Aronhime, Claude Singer, Anita Liebermann, Neomi Gershon
Abstract: An N-containing five-membered ring compound of formula (I) wherein all symbols are the same as described in the specification, and a non-toxic salt thereof. The compound of formula (I) has an inhibitory activity against cysteine protease and therefore it is useful as an agent for the prophylaxis and/or treatment of inflammatory diseases, diseases induced by apoptosis, diseases induced by disorders of immune responses, autoimmune diseases, diseases induced by decomposition of proteins which compose organism, shock, circulatory system disorders, blood coagulation systems disorders, malignant tumors, acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC), parasitic diseases, nerve degeneration diseases, pulmonary disorders, bone resorption diseases, endocrinesthenia, etc.
Abstract: NMDA receptor blockers, including pH-sensitive NMDA receptor blockers, are provided as neuroprotective drugs that are useful in stroke, traumatic brain injury, epilepsy, and other neurologic events that involve acidification of brain or spinal cord tissue. Compositions and methods of this invention are used for treating neurodegeneration resulting from NMDA receptor activation. The compounds described herein have enhanced activity in brain tissue having lower-than normal pH due to pathological conditions such as hypoxia resulting from stroke, traumatic brain injury, global ischemia that may occur during cardiac surgery, hypoxia that may occur following cessation of breathing, pre-eclampsia, spinal cord trauma, epilepsy, chronic pain, vascular dementia and glioma tumors.
Type:
Grant
Filed:
March 8, 2002
Date of Patent:
May 20, 2008
Assignee:
Emory University
Inventors:
Stephen F. Traynelis, Dennis C. Liotta, James P. Snyder, Yesim Altas, David D. Mott, James J. Doherty, Jr., Raymond J. Dingledine
Abstract: A process for producing fluorinated C1 HFCs comprising fluorinating a reactive organic compound to produce a reaction product comprising at least the desired C1 HFC, unreacted reactive organic compound and a byproduct having a boiling point between the boiling point of said desired hydrofluorocarbon compound and said reactive organic compound; and removing from the reaction product at least a substantial portion of the byproduct to produce a high purity product stream.
Type:
Grant
Filed:
October 17, 2003
Date of Patent:
May 13, 2008
Assignee:
Honeywell International Inc.
Inventors:
Rajat S. Basu, Lawrence F. Mullan, Peter H. Scheidle, Steven J. Bass, Addison M. Smith
Abstract: A process for catalytically oxidizing alkylaromatic compounds of the formula (I) Ar—CH2—R where Ar is an optionally substituted, aromatic or heteroaromatic 5-membered or 6-membered ring or a ring system having up to 20 carbon atoms where Ar may optionally be fused to a C1-C6-alkyl group in which up to 2 carbon atoms may be replaced by a heteroatom, and R is hydrogen, phenyl, benzyl or heteroaryl, where the phenyl, benzyl or heteroaryl radicals may also be joined to Ar by a bridge, or R together with Ar forms an optionally substituted ring system which may contain one or more optionally substituted heteroatoms, to the corresponding aromatic or heteroaromatic carboxylic acids in a solvent with ozone in the presence of a transition metal catalyst and optionally in the presence of an acid at a temperature between ?70° C. and 110° C. to the corresponding carboxylic acid.
Type:
Grant
Filed:
May 15, 2003
Date of Patent:
May 13, 2008
Assignee:
DSM Fine Chemicals Austria Nfg GmbH & Co KG
Inventors:
Walther Jary, Peter Poechlauer, Thorsten Ganglberger
Abstract: The invention relates to novel indole derivatives of the general formula 1, to their preparation and to their use as medicaments, in particular for treating tumors
Abstract: The present invention provides therapeutically useful substituted guanidines, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more of such guanidines.
Type:
Grant
Filed:
August 11, 2000
Date of Patent:
April 1, 2008
Assignee:
Wyeth
Inventors:
Stanley M. Goldin, James B. Fischer, Andrew Gannett Knapp, N. Laxma Reddy, David Berlove, Graham J. Durant, Subbarao Katragadda, Lain-Yen Hu, Sharad Magar, Wenhong Fan, Elizabeth Yost, Juo Qing Guo
Abstract: Severely sterically hindered secondary aminoether alcohols are prepared by reacting acid anhydrides or organic carboxylic acid halides with SO3 to yield a sulfonic carboxylic anhydride compound which is then reacted with a dioxane to cleave the ring of the dioxane yielding a cleavage product which is then aminated with an alkylamine and hydrolyzed with a base to yield the severely sterically hindered secondary aminoether alcohol.
Type:
Grant
Filed:
February 1, 2005
Date of Patent:
April 1, 2008
Assignee:
ExxonMobil Research and Engineering Company
Inventors:
Michael Siskin, Alan Roy Katritzky, Kostyantyn Mykolayevich Kirichenko, Adeana Richelle Bishop, Christine Nicole Elia
Abstract: The object of the invention is to provide polyester-based fiber which maintains physical properties of usual polyester fiber, such as heat resistance, strength and elongation and is excellent in setting ability with controlled gloss of the fiber, artificial hair using the same, a method of producing polyester-based fiber, and a method of producing artificial hair by using the same. To achieve the object, a composition obtained by melt-kneading polyalkylene terephthalate or a copolymerized polyester (A) based on polyalkylene terephthalate, polyarylate (B) and a phosphite compound (C) is melt-spun to form fiber. In the case of melt-kneading, the ester exchange reaction of components (A) and (B) is prevented due to the inhibitory effect of the component (C) on the ester exchange reaction, the heat resistance and physical properties of the fiber are not deteriorated, and a matte effect is brought about by formation of protrusions on the surface of the fiber.
Abstract: A compound or a salt thereof having the atom corresponding to N3 and the two or more atoms selected from N1, N2, N4 and N5, said atoms constitute the pharmacophore represented by the following formula: and inhibits the activity of transcription factor AP-1 and is useful as an agent for preventing and treating the diseases into which over expression of AP-1 participates and as an AP-1 inhibitor.
Abstract: Novel benzamide compounds, their salts and compositions related thereto having activity against mammalian Factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.
Type:
Grant
Filed:
April 1, 2002
Date of Patent:
December 25, 2007
Assignee:
Millennium Pharmaceuticals, Inc.
Inventors:
Bing-Yan Zhu, Penglie Zhang, Erick A. Goldman, Zhaozhong Jon Jia, Shawn Bauer, Wenrong Huang, John Woolfrey, Robert M. Scarborough
Abstract: A compound having the following formula: wherein R3 and M are defined herein, and processes therewith.
Type:
Grant
Filed:
August 22, 2003
Date of Patent:
January 1, 2008
Assignee:
Dow AgroSciences LLC
Inventors:
Michael J. Ricks, Richard B. Rogers, William H. Dent, III, Chenglin Yao, Bassam S. Nader, John L. Miesel, Gina M. Fitzpatrick, Kevin G. Meyer, Noormohamad M. Niyaz, Irene M. Morrison, Matthew J. Henry, Jenifer L. Adamski Butz, Robert P. Gajewski